Diane Bouis, PhD MBA (She/Her)
Diane is the outgoing Program Director for MedTech Innovator, the largest Medtech accelerator in the world and an advisor and investor to female led-biomedical startups.
She has extensive experience managing startup portfolios through previous roles as Innovation Manager at the University of Michigan’s Innovation Partnerships Startup Incubator and as an innovation consultant with The Inovo Group.
She has lived and worked on three continents, speaks six languages, holds a PhD on gene therapy in oncology from the University of Groningen, Netherlands and an MBA from the University of Michigan Ross School of Business.
To learn more about Diane visit Linkedin
Ted L. Liberti, CCO, Co-Founder, BioMagnetic SolutionTed co-founded BioMagnetic Solutions (BioMag) in 2012 and has served as BioMag’s COO, CEO, CBO, CCO and EVP of Business Development, managing BioMag’s operations, business development and corporate partnering initiatives for BioMag’s cell selection technologies and cell therapy platforms.
He is an expert on magnetic cell selection and the manufacture and optimizations of BioMag’s core technology – nanomagnetic Ferrofluids for biological and cell separations. In 2021, after 11 years of R&D, BioMag completed a private-equity deal with KKR-backed Gamma Biosciences to bring BioMagnetic Solutions’ FerroSelect™ Array cell selection system to market. BioMag’s FerroSelect™ Array system leverages BioMag’s key scientific superpower – Ferrofluids. Ferrofluids are nanomagnetic liquids (magnetic particles/beads) for bioseparations for selecting: cells, DNA, proteins, exosomes, circulating tumor cells**, rare cells & more). BioMag’s FerroSelect™ cell selection system provides immunomagnetic selection for the manufacture of CAR-T cell & gene therapy (CGT) products. FerroSelect™ provides CDMOs and CAR-T groups a true path to GMP CAR-T cell manufacture in the clinic. BioMag’s FerroSelect™ Array cell selection system is an automated immunomagnetic system driven by BioMag’s universal “Common Capture” Ferrofluids and uses a 2-step indirect mAb labeling process for process development (PD) and GMP CAR-T product manufacture.
Ted co-founded BioMag with the acclaimed scientist and inventor Paul A. Liberti, PhD. BioMag is the successor to Immunicon Corp. (NASDAQ: IMMC) where Liberti developed CELLSEARCH® ** ~ the only FDA-approved circulating tumor cell (CTC) assay marketed & owned by J&J’s Janssen unit & acquired by Menarini’s Silicon BioSystems in 2018.
Ted holds a B.S. from The Pennsylvania State University and an M.A. in Applied Economics from the University of Delaware. He completed doctoral research in economics, strategy, networks and entrepreneurship at Penn State’s Smeal College of Business and holds an MBA in international corporate strategy from the University of Delaware with high honors. Fluent in French, he started his career in international banking with JP Morgan Paris, leveraging his economics, finance, and language skills in investment banking. Later with Immunicon Corp., he assisted with business development, business strategy, contract research projects, and collaborations with bioMérieux S.A., Guerbet S.A., and French academic groups in Paris and Lyon. Ted advised on the valuation of Immunicon’s MRI contrast agent patents, leading to a $1M licensing arrangement with Sweden’s Nycomed Pharmaceuticals. From 2006 to 2012, he worked with Ben Franklin Technology Partners’ portfolio of life science, medical device, IT, and industrial firms. His career passions are: science, helping to solve extremely thorny scientific problems and building world-class biotech biotech companies that change and inflect human health with powerful technologies.